Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (28)	5/10/2002 4:26:02 PM
From: scaram(o)uche	Read Replies (1) of 684

>> yet << As far as I'm concerned, it could be "never". Both business plans have soured, IMO. Would love to be wrong. So what's the difference? VGNX practices an art that is in demand. The CEO is history. An offer at cash might corner a going concern that is of pivotal need to a pharma, looking forward. The guy who posts at Yahoo, Due Diligence? I didn't like his insensitive stance re. the existing projects and those who believe in them. Otherwise, I agreed and agree with him. I've lost track..... I know that an offer at cash would more than make me whole, but that reflects one heck of a lot of averaging down. I don't know how much burn could pass before such would not be true. :-(

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next